170 related articles for article (PubMed ID: 38467634)
1. Delivery of a BET protein degrader via a CEACAM6-targeted antibody-drug conjugate inhibits tumour growth in pancreatic cancer models.
Nakazawa Y; Miyano M; Tsukamoto S; Kogai H; Yamamoto A; Iso K; Inoue S; Yamane Y; Yabe Y; Umihara H; Taguchi J; Akagi T; Yamaguchi A; Koga M; Toshimitsu K; Hirayama T; Mukai Y; Machinaga A
Nat Commun; 2024 Mar; 15(1):2192. PubMed ID: 38467634
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma.
Strickland LA; Ross J; Williams S; Ross S; Romero M; Spencer S; Erickson R; Sutcliffe J; Verbeke C; Polakis P; van Bruggen N; Koeppen H
J Pathol; 2009 Jul; 218(3):380-90. PubMed ID: 19334050
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of novel anti-CEACAM6 antibody-based conjugates for radioimmunotheranostics of pancreatic ductal adenocarcinoma.
Kong Y; Xie F; Zhang Z; Wang S; Zhang Y; Di Y; Zhou Z; Jiang D; Li J; Huang Q; Wang J; Li X; Pan Z; Ni R; Guan Y
Eur Radiol; 2023 Oct; 33(10):7077-7088. PubMed ID: 37166496
[TBL] [Abstract][Full Text] [Related]
4. Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody-Drug Conjugates in Pancreatic Cancer.
Tsujii S; Serada S; Fujimoto M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Mol Cancer Ther; 2021 Dec; 20(12):2495-2505. PubMed ID: 34583978
[TBL] [Abstract][Full Text] [Related]
5. An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer.
Bourillon L; Bourgier C; Gaborit N; Garambois V; Llès E; Zampieri A; Ogier C; Jarlier M; Radosevic-Robin N; Orsetti B; Delpech H; Theillet C; Colombo PE; Azria D; Pèlegrin A; Larbouret C; Chardès T
Int J Cancer; 2019 Oct; 145(7):1838-1851. PubMed ID: 30882895
[TBL] [Abstract][Full Text] [Related]
6. Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) in Pancreatic Ductal Adenocarcinoma (PDA): An integrative analysis of a novel therapeutic target.
Pandey R; Zhou M; Islam S; Chen B; Barker NK; Langlais P; Srivastava A; Luo M; Cooke LS; Weterings E; Mahadevan D
Sci Rep; 2019 Dec; 9(1):18347. PubMed ID: 31797958
[TBL] [Abstract][Full Text] [Related]
7. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
[TBL] [Abstract][Full Text] [Related]
8. Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment.
Huang Y; Nahar S; Nakagawa A; Fernandez-Barrena MG; Mertz JA; Bryant BM; Adams CE; Mino-Kenudson M; Von Alt KN; Chang K; Conery AR; Hatton C; Sims RJ; Fernandez-Zapico ME; Wang X; Lillemoe KD; Fernández-Del Castillo C; Warshaw AL; Thayer SP; Liss AS
Clin Cancer Res; 2016 Aug; 22(16):4259-70. PubMed ID: 27169995
[TBL] [Abstract][Full Text] [Related]
9. Single domain antibody against carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) inhibits proliferation, migration, invasion and angiogenesis of pancreatic cancer cells.
Cheng TM; Murad YM; Chang CC; Yang MC; Baral TN; Cowan A; Tseng SH; Wong A; Mackenzie R; Shieh DB; Zhang J
Eur J Cancer; 2014 Mar; 50(4):713-21. PubMed ID: 22918079
[TBL] [Abstract][Full Text] [Related]
10. Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer.
Nishigaki T; Takahashi T; Serada S; Fujimoto M; Ohkawara T; Hara H; Sugase T; Otsuru T; Saito Y; Tsujii S; Nomura T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Nakajima K; Eguchi H; Yamasaki M; Mori M; Doki Y; Naka T
Br J Cancer; 2020 Apr; 122(9):1333-1341. PubMed ID: 32152502
[TBL] [Abstract][Full Text] [Related]
11. Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer.
Riley CJ; Engelhardt KP; Saldanha JW; Qi W; Cooke LS; Zhu Y; Narayan ST; Shakalya K; Croce KD; Georgiev IG; Nagle RB; Garewal H; Von Hoff DD; Mahadevan D
Cancer Res; 2009 Mar; 69(5):1933-40. PubMed ID: 19244123
[TBL] [Abstract][Full Text] [Related]
12. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
13. Impacting Pancreatic Cancer Therapy in Heterotypic
Obaid G; Bano S; Mallidi S; Broekgaarden M; Kuriakose J; Silber Z; Bulin AL; Wang Y; Mai Z; Jin W; Simeone D; Hasan T
Nano Lett; 2019 Nov; 19(11):7573-7587. PubMed ID: 31518145
[TBL] [Abstract][Full Text] [Related]
14. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
15. CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Oncogene; 2004 Jan; 23(2):465-73. PubMed ID: 14724575
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Bromodomain Proteins Enhances Oncolytic HAdVC5 Replication and Efficacy in Pancreatic Ductal Adenocarcinoma (PDAC) Models.
Miao T; Symonds A; Hickman OJ; Wu D; Wang P; Lemoine N; Wang Y; Linardopoulos S; Halldén G
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279262
[TBL] [Abstract][Full Text] [Related]
17. Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus.
Moore KM; Desai A; Delgado BL; Trabulo SMD; Reader C; Brown NF; Murray ER; Brentnall A; Howard P; Masterson L; Zammarchi F; Hartley JA; van Berkel PH; Marshall JF
Theranostics; 2020; 10(7):2930-2942. PubMed ID: 32194845
[No Abstract] [Full Text] [Related]
18. Molecular targeting of CEACAM6 using antibody probes of different sizes.
Niu G; Murad YM; Gao H; Hu S; Guo N; Jacobson O; Nguyen TD; Zhang J; Chen X
J Control Release; 2012 Jul; 161(1):18-24. PubMed ID: 22568933
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma.
Nagaoka K; Bai X; Ogawa K; Dong X; Zhang S; Zhou Y; Carlson RI; Jiang ZG; Fuller S; Lebowitz MS; Ghanbari H; Wands JR
Cancer Lett; 2019 May; 449():87-98. PubMed ID: 30768955
[TBL] [Abstract][Full Text] [Related]
20. CEACAM6 induces epithelial-mesenchymal transition and mediates invasion and metastasis in pancreatic cancer.
Chen J; Li Q; An Y; Lv N; Xue X; Wei J; Jiang K; Wu J; Gao W; Qian Z; Dai C; Xu Z; Miao Y
Int J Oncol; 2013 Sep; 43(3):877-85. PubMed ID: 23857344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
